Skip to main content
. 2018 May 22;9(39):25557–25571. doi: 10.18632/oncotarget.25374

Table 6. Significant Genes based on 10% differences of methylation level between Cancer and Control (hypo-methylated genes).

Gene Regions DMR location Distance To TSS Methylation Difference Gene Role
Start End % P q
SLC2A3 Intron 8,087,820 8,087,905 988 -61.18 1.06E-13 6.23E-12 Glucose transporter 3 (GLUT3)
MLH3 Promoter 75,518,893 75,518,943 -659 -51.32 2.22E-07 1.73E-06 DNA mismatch repair genes
SLC2A1 Promoter 43,425,368 43,425,715 -522 -44.71 8.39E-10 1.51E-08 Glucose transporter 1 (GLUT1)
FCN1 Intron 137,802,212 137,802,301 7,506 -28.36 6.39E-04 1.33E-03 Associated with Diabetes
SEPT9 Intron 75,449,408 75,450,396 0 -27.68 2.50E-09 3.82E-08 Tumor suppressor gene
PEMT Intron 17,410,253 17,410,397 -10,545 -23.01 9.47E-05 2.77E-04 Methylation pathway
ALDH1L1 Intron 125,832,461 125,832,876 9,980 -11.08 9.75E-04 1.86E-03 Methylation pathway